CClinicalTrials.gg
CompletedNCT03438084INTER-CARDIOUpdated Jan 27, 2020

The INTER-CARDIO Study: The Impact of Commonly Consumed Fat on Cardiovascular Health; a Randomised Controlled Trial

An interventional study of Interesterified fat and Non- interesterified fat in Healthy Adults, sponsored by King's College London. Completed at 2 sites in United Kingdom. Open to participants aged 35 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-27.

Sponsored by King's College London · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to investigate whether there are differences in postprandial cardiometabolic metabolic indices following interesterified fats used commercially versus application appropriate non- interesterifed alternative fat.

Read the detailed description

Aim: The current study aims to investigate the acute effects of commercially available interesterified fat versus versus application appropriate non- interesterifed alternative fat on 8 h postprandial cardiometabolic outcomes.

Hypothesis: Interesterified fat will induce a different cardiomtabolic response compared to a non interesterifed, application appropriate fat.

Subjects: Participants will include 40 healthy male and female volunteers aged between the ages of 35 and 75 years (since during this age metabolic changes start to take place).

Power calculation: Based on previous studies carried out by our group at King's College London, a sample size of 20 participants (males and females separately) will allow a 2.16% (percentage unit) difference in FMD to be detected (90% power, 0.05 alpha, SD 2.9. 50 participants will be recruited allowing for a 20% dropout rate.

Expected value:The study will provide novel information on the acute effects of commercially relevant processed fats on postprandial lipaemia.

02

Conditions studied

  • Healthy Adults

Keywords

  • Interesterified
  • Postprandial
  • Lipid
03

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Males and females aged 35-75 years
  • Healthy (free of diagnosed diseases listed in exclusion criteria)
  • Able to understand the information sheet and willing to comply with study protocol
  • Able to give informed consent

Exclusion criteria

Exclusion Criteria:

  • Medical history of myocardial infarction, angina, thrombosis, stroke, cancer, liver or bowel disease or diabetes
  • Body mass index \< 20 kg/m2 or > 35 kg/m2
  • Plasma cholesterol ≥7.5 mmol/L
  • Plasma triacylglycerol > 3 mmol/L
  • Plasma glucose > 7 mmol/L
  • Blood pressure ≥140/90 mmHg
  • Current use of antihypertensive or lipid lowering medications
  • Alcohol intake exceeding a moderate intake (> 28 units per week)
  • Current cigarette smoker (or quit within the last 6 months)
  • ≥ 20% 10-year risk of CVD as calculated using a risk calculator
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Interesterified

    Commercially available interesterifed fat spread. 50g fat.

    Dietary Supplement: Interesterified fat

  • Active comparator
    Non- interesterified

    Commercially available non-interesterified fat. 50g fat.

    Dietary Supplement: Non- interesterified fat

  • Active comparator
    Control

    Rapeseed oil. 50 g fat.

    Dietary Supplement: Rapeseed oil

  • Active comparator
    Saturated fat control

    Butter. 50g fat

    Dietary Supplement: Butter

Interventions

  • Dietary supplementInteresterified fat

    50 g fat provided as commercially available interesterified fat.

  • Dietary supplementNon- interesterified fat

    50 g fat provided as commercially available non-interesterified fat.

  • Dietary supplementRapeseed oil

    50 g fat provided as commercially available rapeseed oil.

  • Dietary supplementButter

    50g fat provided as commercially available spreadable butter

05

What researchers measure

Primary outcomes

  1. Endothelial function

    Flow mediated dilatation

    Time frame: Up to 8 hours

  2. Postprandial lipaemic response

    Area under plasma TAG concentration/ time curve

    Time frame: Up to 8 hours

Secondary outcomes

  1. Postprandial lipaemic response

    Postprandial plamsa total fatty acid composition and non esterifed fatty acid

    Time frame: Up to 8 hours

  2. Metabolomic for assessment of atherogenic potential (lipoprotein) analysis

    Lipid concentrations and compositions of 14 lipoprotein subclasses, measured by NMR

    Time frame: Up to 8 hours

  3. Glycaemic response

    Plasma glucose concentration

    Time frame: Up to 8 hours

  4. Insulinaemic response

    Plasma insulin concnetration

    Time frame: Up to 8 hours

  5. Nitric oxide bioavailability

    Plasma nitric oxide species and NADPH oxidase activity

    Time frame: Up to 8 hours

  6. Oxidative stress

    Plasma 8-isoprostane F2a

    Time frame: Up to 8 hours

  7. Inflammatory response

    Plasma IL-6

    Time frame: Up to 8 hours

06

Study locations

2 sites
  • Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, Kings College London
    London, SE1 9NH, United Kingdom
  • King's College London
    London, SE1 9NH, United Kingdom
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03438084
Lead sponsor
King's College London
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Jul 1, 2018
Primary completion
Oct 1, 2019
Completion
Oct 31, 2019
Last update
Jan 27, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion